Key result
Novel model combining GlycA, HDL1-TC, and clinical factors predicts T2D complications with ~0.82 AUC.
Why the study?
Does a risk assessment model based on GlycA and HDL1-TC improve type 2 diabetes complication risk stratification compared to HbA1c/hs-CRP in adults with T2DM?
Cross-Sectional (n=228)
Yes
Does a risk assessment model based on GlycA and HDL1-TC improve type 2 diabetes complication risk stratification compared to HbA1c/hs-CRP in adults with T2DM?
Effect estimate: AUC 0.82 (95% CI 0.756-0.873)
A novel risk assessment model incorporating NMR-derived GlycA and HDL1-TC provides good discrimination for stratifying complication risk in patients with type 2 diabetes.
Background This study evaluated NMR-derived GlycA and lipoprotein subfractions for stratifying type 2 diabetes (T2DM) complication risk. Methods A retrospective cross-sectional study included 228 adults with T2DM from two hospitals between January and December 2023. Clinical variables, the NMR-derived inflammatory markers GlycA and GlycB, and lipoprotein subfractions were analyzed. A stepwise logistic model was assessed by ROC analysis, Hosmer–Lemeshow test, bootstrap calibration, and decision-curve analysis. Results Age, diabetes duration, fasting plasma glucose, GlycA, and HDL1-TC were retained. The model showed good fit (χ² = 7.141, P = 0.521), discrimination (AUC = 0.82, 95% CI: 0.756–0.873), calibration (MAE = 0.021), and higher net benefit than HbA1c/hs-CRP. Conclusions A model integrating GlycA, HDL1-TC, and clinical factors showed good performance for T2DM complication risk stratification, but causal inference and temporal prediction cannot be established because of the cross-sectional design.
No takes yet. Share an insight, caveat, or question.
Kou et al. (2026) conducted a cross-sectional in Type 2 diabetes complications (n=228). Risk assessment model integrating GlycA, HDL1-TC, and clinical factors vs. HbA1c/hs-CRP was evaluated on Model discrimination for type 2 diabetes complication risk (AUC 0.82, 95% CI 0.756-0.873). A risk assessment model integrating GlycA, HDL1-TC, and clinical factors showed good discrimination for type 2 diabetes complication risk (AUC 0.82; 95% CI 0.756-0.873).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: